retatrutide clinical trial results weight loss Lilly orforglipron oral GLP-1 phase 3 Retatrutide Weight Loss Results:Trial Data

Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4

Severe GERD or reflux Delayed emptying can worsen reflux symptoms

Clinical trials of semaglutide and tirzepatide have not shown direct suppression of thyroid hormone synthesis, meaning these medications do not inherently worsen hypothyroidism when properly monitored

Elsewhere, a novel ingredient made from pulses and legumes has also been developed to stimulate GLP-1 release

Fever or Infection Signs: The presence of fever, along with back pain, may suggest an underlying infection in the spine

The gastrointestinal adverse events associated with GLP-1 receptor agonists are typically dose-dependent, transient, and manageable with slow titration (Meier, Diabetes, Obesity and Metabolism )